Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1841387 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $9.68Day −2.81%Mkt cap $709M1Y +41.1%Off 52W high −14.8%Vol (1Y) 71.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,122 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest17.7% of sh out |
| Days to cover9.0d |
| 13F net flow (QoQ)+7.34% |
| Top-10 13F concentration81.7% |
| Next report (est.)2026-08-13 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$125,000 |
| Earnings (TTM)-$54.4M |
| ROE−64.6% |
| Debt / equity0.00× |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+71.3% |
| 1Y+41.1% |
| 3Y+821.9% |
| 5Y+40.5% |
| Since incept. (ann.)+7.0% |
Total return through 2026-07-28 · series begins 2021-07-28. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)71.0% |
| Ann. volatility (3Y)196.1% |
| Sharpe (1Y)0.84 |
| Sharpe (3Y)0.91 |
| Max drawdown (1Y)−35.6% |
| Max drawdown (3Y)−72.9% |
| Beta (3Y vs SPY)−2.32 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 11.0M | $54M | 15.00% | +33.4% |
| RTW INVESTMENTS, LP | 6.4M | $31M | 8.76% | new |
| ACORN CAPITAL ADVISORS, LLC | 3.5M | $17M | 4.77% | +35.6% |
| BlackRock, Inc. | 3.1M | $15M | 4.24% | +8.6% |
| Saturn V Capital Management LP | 2.9M | $14M | 3.95% | new |
| Portolan Capital Management, LLC | 2.9M | $14M | 3.95% | +70.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5M | $12M | 3.36% | new |
| Vestal Point Capital, LP | 1.1M | $6M | 1.54% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | −$0.14 | −207.7% | — | — |
| 2025-09-30 | 2025-11-13 | −$0.21 | — | — | — |
| 2025-06-30 | 2025-08-14 | −$0.09 | — | — | — |
| 2025-03-31 | 2025-05-13 | $0.13 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-13 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
